Helmi Anwar

🩺 Community Question: Elon Musk recently said that, based on current human constraints, AI-powered robotics could become better surgeons than the best human surgeons within three years at scale. Do you agree with him? Viewpoint A: Agree. With few great surgeons, slow and costly human training, and unavoidable human error, AI and robotics could learn faster and scale surgical skill beyond human limits. Viewpoint B: Disagree. Even acknowledging the human constraints Elon Musk points out, surgery is not only about speed, scale, or error reduction. It also depends on judgment, responsibility, and trust in high-stakes situations, which remain difficult to validate and deploy safely at scale. Is this a near-term breakthrough or a vision that overestimates how quickly surgical autonomy can be safely scaled? 👇 Drop A, B, or share your perspective.

💊 Community Question: Can AI help discover and develop new medicines much faster and cheaper than traditional methods? Viewpoint A: Yes. AI can rapidly test millions of drug ideas, cut early research time and costs dramatically, and in some cases bring medicines to patients years faster. Viewpoint B: Not fully. AI helps at the start, but human trials are still slow, expensive, and unpredictable, keeping overall drug development costly and time-consuming. If AI is expected to change how medicines are made, is the impact already real or mostly promise? 👇 Drop A, B, or share your perspective.

🩺 Community Question Is personalized care realistic for low- and middle-income countries (LMICs), or is it still a model built mainly for high-income countries (HICs)? Viewpoint A: Gradually achievable in LMICs Personalized care can scale over time. Costs of genetic and digital tools are falling, AI-driven insights are becoming more accessible, and hybrid models already work in areas like oncology and chronic care. With the right partnerships and focus, personalization doesn’t have to remain a luxury. Viewpoint B: Not practical for most LMICs For many LMICs, personalized care remains unrealistic. High costs, limited infrastructure, workforce gaps, and unequal access make large-scale adoption difficult. Healthcare systems should prioritize proven, low-cost interventions like vaccination, screening, and basic prevention. Or is the future of healthcare built by combining both approaches? 👇 Drop A, B, or share your perspective. Tag someone who should weigh in on this.

🩺Community Question: Should healthcare prioritize personalized care for individuals, or one-size-fits-all care for everyone? Viewpoint A: One-size-fits-all as the default Standardized care is more practical, affordable, and equitable for large populations and resource-limited settings. It delivers consistent, proven outcomes at scale, reduces disparities, and avoids the high cost and access barriers of full personalization. Viewpoint B: Shift to personalized care Personalized care is more precise, effective, and preventive. Leveraging genetics, AI, and real-world insights enables better outcomes, fewer side effects, and long-term cost savings as personalization becomes increasingly accessible. Have you benefited from standardized care or struggled because it wasn’t personalized enough? 👇 Share A, B, or a short personal insight. Tag someone who should be part of this conversation.

🩺 Community question: Where will the next major breakthrough in healthcare come from? Viewpoint A: From established systems like the US and UK where world-class institutions, funding, and decades of research infrastructure continue to drive innovation. Viewpoint B: From outside traditional power centers where emerging regions, new models, and fewer legacy constraints enable faster experimentation and unexpected breakthroughs. Which side do you believe in and why? 👇 Drop A, B, or share your perspective. Tag someone who should weigh in on this.